Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Multiple Myeloma Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU d'Amiens, Amiens, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

With multiple myeloma
Who receive Teclistamab
Consent form signed

Exclusion criteria

Patient under legal protection

Treatment and study plan

Bone marrow sampling

Other

Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)

Primary outcomes

Response to teclistamab at 12 weeks

Time frame: at day 1 Cycle 4 (each cycle is 28 days)

response according to International Myeloma Working Group criteria

Study contacts

Contact information is provided by the study sponsor or research team.

Hervé AVET LOISEAU, MD, PhD

CONTACT

[email protected]

+33 531 156 142 ext. 33

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Acronym: ResisTec

Important dates

Study start: 2023
Primary completion: 2026
Study completion: 2026
First posted: Jul 14, 2023
Registry last updated: Apr 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting